• Publications
  • Influence
A new depression scale designed to be sensitive to change.
The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described, and its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change. Expand
Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study.
The findings provide a set of 11 relevant clinical variables associated with treatment resistance in major depressive disorder that can be explored at the clinical level and show that comorbid anxiety disorder is the most powerful clinical factor associated with TRD. Expand
Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine.
Pregabalin was safe, well tolerated, and rapidly efficacious across the physical-somatic as well as the emotional symptoms of GAD in the majority of patients studied in primary care and psychiatric settings. Expand
Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia.
Odds ratios revealed that generalized anxiety disorder is significantly more likely to co-occur with dysthymia than with bipolar or unipolar depression, and panic disorder showed a higher trend to be associated with bipolar and un bipolar depression. Expand
Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment.
The first, large scale, placebo-controlled study to assess the efficacy of drug treatment in generalized social phobia has been completed with paroxetine, which was more effective in reducing the symptoms than placebo and was well tolerated. Expand
Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.
Quetiapine XR monotherapy is effective, with safety and tolerability consistent with the known profile of quetiapsin XR, in the treatment of patients with MDD, with onset of symptom improvement demonstrated at week 1. Expand
Social functioning in depression: a review.
This article reviews the available data on social functioning in depression and provides clinical guidelines and opinion on this important and expanding field and it is becoming clear that not all treatments are equally effective in relieving the impaired social functioning associated with depressive disorders. Expand
Lack of Efficacy of the Substance P (Neurokinin1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder
Because the methodology employed confirmed the antidepressant efficacy of paroxetine, the absence of an effect for aprepitant indicates that it was not an effective treatment for depression. Expand
Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey
Overall, the results show that DSM‐IV GAD is associated with high impairment even after controlling for other psychopathology, and the impairment outcomes for GAD were comparable in size to those for MDD. Expand
A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake
This randomised, double‐blind, 12‐week study compared efficacy and tolerability of flexible‐dose treatment with vortioxetine (10–20 mg/day) versus agomelatine (25–50 mg/day) in major depressiveExpand